Observational studyRespiratory research2017
The value of blood cytokines and chemokines in assessing COPD.
Observational study in Respiratory research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Subpopulations and Intermediate Outcome Measures in COPD Study
COPDGene/Lung Cancer Center Database
Who cites it
65 citing papers in PubMed, 117 citations in OpenAlex.
- Extracorporeal photopheresis as induction therapy in lung transplantation for cystic fibrosis: a pilot randomized trial.Frontiers in immunology · 2025Trial
- Assessment of risk factors responsible for rapid deterioration of lung function over a period of one year in patients with chronic obstructive pulmonary disease.Scientific reports · 2021Trial
- Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial.BMJ open respiratory research · 2019Trial
- The elevated CXCL5 levels in circulation are associated with lung function decline in COPD patients and cigarette smoking-induced mouse model of COPD.Annals of medicineTrial
- Eosinophil biology in COPD: from scientific insight to clinical treatment action.ERJ open research · 2026Review
- Seeing is believing-on the utility of CT in phenotyping chronic obstructive pulmonary disease.The British journal of radiology · 2026Review
- Activation of STAT3 in the COPD airway epithelium.ERJ open research · 2026Article
- Article
- Association of Lung Quantitative CT Scan Textures With Systemic Inflammation and Mortality in COPD.Chest · 2025Article
- An Integrated Strategy for Preventing and Rehabilitating Dust-Induced Occupational Bronchopulmonary Diseases: A Scoping Review.Advances in respiratory medicine · 2025Article
- Article
- Prognostic Value of Biomarkers in Chronic Obstructive Pulmonary Disease: A Comprehensive Review.International journal of chronic obstructive pulmonary disease · 2025Review
- Analysis of immune characteristics and inflammatory mechanisms in COPD patients: a multi-layered study combining bulk and single-cell transcriptome analysis and machine learning.Frontiers in medicine · 2025Article
- IL-6 and CD4Journal of inflammation research · 2025Article
- The Mediation of Circulating Inflammatory Proteins in the Causal Pathway from Immune Cells to COPD.International journal of chronic obstructive pulmonary disease · 2025Article
- A novel chronic obstructive pulmonary disease mouse model induced by intubation-mediated intratracheal co-administration of porcine pancreatic elastase and lipopolysaccharide.BMC pulmonary medicine · 2024Article
- Article
- Proteomic networks and related genetic variants associated with smoking and chronic obstructive pulmonary disease.BMC genomics · 2024Article
- Roles of Inflammatory Biomarkers in Exhaled Breath Condensates in Respiratory Clinical Fields.Tuberculosis and respiratory diseases · 2024Article
- Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundBlood biomarkers are increasingly used to stratify high risk chronic obstructive pulmonary disease (COPD) patients; however, there are fewer studies that have investigated multiple biomarkers and replicated in multiple large well-characterized cohorts of susceptible current and former smokers.
methodsWe used two MSD multiplex panels to measure 9 cytokines and chemokines in 2123 subjects from COPDGene and 1117 subjects from SPIROMICS. These biomarkers included: interleukin (IL)-2, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, eotaxin/CCL-11, eotaxin-3/CCL-26, and thymus and activation-regulated chemokine (TARC)/CCL-17. Regression models adjusted for clinical covariates were used to determine which biomarkers were associated with the following COPD phenotypes: airflow obstruction (forced expiratory flow at 1 s (FEV
resultsEotaxin and IL-6 were strongly associated with airflow obstruction and accounted for 3-5% of the measurement variance on top of clinical variables. IL-6 was associated with progressive airflow obstruction over 5 years and both IL-6 and IL-8 were associated with progressive emphysema over 5 years. None of the biomarkers were consistently associated with chronic bronchitis or COPD exacerbations. We identified one novel SNP (rs9302690 SNP) that was associated with CCL17 plasma measurements.
conclusionWhen assessing smoking related pulmonary disease, biomarkers of inflammation such as IL-2, IL-6, IL-8, and eotaxin may add additional modest predictive value on top of clinical variables alone.
trial registrationCOPDGene (ClinicalTrials.gov Identifier: NCT02445183 ). Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS) ( ClinicalTrials.gov Identifier: NCT 01969344 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.